ATE329045T1 - Verfahren zur aufreinigung von rekombinanten, viralen vektoren welche ein therapeutisches gen enthalten - Google Patents

Verfahren zur aufreinigung von rekombinanten, viralen vektoren welche ein therapeutisches gen enthalten

Info

Publication number
ATE329045T1
ATE329045T1 AT96911282T AT96911282T ATE329045T1 AT E329045 T1 ATE329045 T1 AT E329045T1 AT 96911282 T AT96911282 T AT 96911282T AT 96911282 T AT96911282 T AT 96911282T AT E329045 T1 ATE329045 T1 AT E329045T1
Authority
AT
Austria
Prior art keywords
purification
viral vectors
vectors containing
recombinant viral
therapeutic gene
Prior art date
Application number
AT96911282T
Other languages
English (en)
Inventor
Paul W Shabram
Bernard G Huyghe
Xiaodong Liu
H Michael Shepard
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Application granted granted Critical
Publication of ATE329045T1 publication Critical patent/ATE329045T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F265/00—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00
    • C08F265/02—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00 on to polymers of acids, salts or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D11/00—Inks
    • C09D11/02—Printing inks
    • C09D11/10—Printing inks based on artificial resins
    • C09D11/106—Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT96911282T 1995-03-07 1996-03-06 Verfahren zur aufreinigung von rekombinanten, viralen vektoren welche ein therapeutisches gen enthalten ATE329045T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/400,793 US5837520A (en) 1995-03-07 1995-03-07 Method of purification of viral vectors

Publications (1)

Publication Number Publication Date
ATE329045T1 true ATE329045T1 (de) 2006-06-15

Family

ID=23585038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96911282T ATE329045T1 (de) 1995-03-07 1996-03-06 Verfahren zur aufreinigung von rekombinanten, viralen vektoren welche ein therapeutisches gen enthalten

Country Status (12)

Country Link
US (1) US5837520A (de)
EP (2) EP0813606B1 (de)
JP (2) JP3858200B2 (de)
AR (1) AR001177A1 (de)
AT (1) ATE329045T1 (de)
AU (1) AU5421396A (de)
DE (1) DE69636217T2 (de)
DK (1) DK0813606T3 (de)
ES (1) ES2264801T3 (de)
PT (1) PT813606E (de)
WO (1) WO1996027677A2 (de)
ZA (1) ZA961849B (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738319A4 (de) * 1994-01-12 2000-03-29 Genetic Therapy Inc Reinigung von retroviralen Vektoren
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
EP0847442A1 (de) 1995-08-30 1998-06-17 Genzyme Corporation Chromatographische reinigung von adenoviren und aav
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
EP0944717A1 (de) * 1996-07-01 1999-09-29 Aventis Pharma S.A. Methode zur produktion von rekombinantem adenovirus.
US6576133B2 (en) 1996-11-13 2003-06-10 Transgenomic, Inc Method and system for RNA analysis by matched ion polynucleotide chromatography
US6475388B1 (en) 1996-11-13 2002-11-05 Transgenomic, Inc. Method and system for RNA analysis by matched ion polynucleotide chromatography
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
BR9713368A (pt) * 1996-11-20 2001-09-18 Introgen Therapeutics Inc Processo melhorado para a produção e a purificação de vetores adenovirais
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6177559B1 (en) 1998-04-24 2001-01-23 Transgenomic, Inc. Process for separation of polynucleotide fragments
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ES2557997T3 (es) 1997-09-05 2016-02-01 Genzyme Corporation Métodos para generar preparados de vectores AAV de título elevado sin virus auxiliar
CA2304375A1 (en) * 1997-10-09 1999-04-22 Biogen, Inc. Chromatographically concentrated baculovirus and methods
US6258264B1 (en) 1998-04-10 2001-07-10 Transgenomic, Inc. Non-polar media for polynucleotide separations
US6265168B1 (en) 1998-10-06 2001-07-24 Transgenomic, Inc. Apparatus and method for separating and purifying polynucleotides
EA200001096A1 (ru) * 1998-04-22 2001-04-23 Джинвек, Инк. Способ обогащения раствора аденовируса, способ точного подсчета числа аденовирусных частиц в образце раствора (варианты) и способ очистки аденовируса из клеток, инфицированных аденовирусом
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
DK1930418T3 (da) 1998-09-04 2015-07-13 Genzyme Corp Fremgangsmåder til frembringelse af hjælperfri præparater med høj titer af frigjorte rekombinante AAV-vektorer
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
KR100762033B1 (ko) 1998-12-31 2007-10-04 아방티 파르마 소시에테 아노님 바이러스 입자의 분리방법
WO2000050573A1 (fr) * 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
DE19933719A1 (de) * 1999-07-19 2001-01-25 Medigene Ag Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
US6464976B1 (en) 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
US6316185B1 (en) 1999-09-29 2001-11-13 Mountain View Pharmaceuticals, Inc. Quantitation of viruses by light scattering
JP4684434B2 (ja) * 2000-02-16 2011-05-18 Ｊｓｒ株式会社 ウイルス濃縮用粒子、ウィルス濃縮用試薬、ウイルス濃縮方法およびウイルス検出方法
DE10010342A1 (de) 2000-03-06 2001-09-20 Merck Patent Gmbh Verfahren zur Abreicherung von Endotoxinen
AU2001275191A1 (en) * 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
US20020064860A1 (en) * 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
US20040093623A1 (en) * 2000-12-20 2004-05-13 Zeger Debyser Non-human animal disease models
KR100451308B1 (ko) * 2001-12-28 2004-10-06 선바이오(주) 단백질 의약품 정제 방법에서의 바이러스 제거 방법
US6833238B2 (en) 2002-01-04 2004-12-21 Applera Corporation Petal-array support for use with microplates
WO2003070891A2 (en) * 2002-02-20 2003-08-28 Merck & Co., Inc. Method of determining adenovirus particle concentration
JP2005521417A (ja) * 2002-03-29 2005-07-21 メルク　エンド　カムパニー　インコーポレーテッド アデノウイルスの大規模産生方法及びアデノウイルス種子ストック
AU2003226012B2 (en) * 2002-03-29 2007-05-24 Merck Sharp & Dohme Corp. Methods of virus production
AU2003229060A1 (en) * 2002-05-14 2003-12-02 Merck And Co., Inc. Methods of adenovirus purification
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
US20040016702A1 (en) * 2002-07-26 2004-01-29 Applera Corporation Device and method for purification of nucleic acids
US20040106184A1 (en) * 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
AU2004249199B2 (en) * 2003-06-18 2008-07-24 Onyx Pharmaceuticals, Inc. Method for purifying virus
CA2531773A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
CA2546287C (en) * 2003-11-24 2014-04-22 Canji, Inc. Reduction of dermal scarring
EP1697505A1 (de) * 2003-12-23 2006-09-06 Schering Corporation Methoden zur herstellung von a549 zelllinien, die in serumfreiem medium in suspensionskultur stabil sind
SG150501A1 (en) * 2004-02-05 2009-03-30 Millipore Corp Porous adsorptive or chromatographic media
US20050181378A1 (en) * 2004-02-18 2005-08-18 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20060160122A1 (en) * 2004-02-18 2006-07-20 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20050196856A1 (en) * 2004-02-18 2005-09-08 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
AU2005214090B2 (en) * 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
WO2006011580A1 (ja) * 2004-07-27 2006-02-02 Genomidea, Inc. ウイルスエンベロープの精製方法
EP1815029A4 (de) * 2004-11-03 2009-06-10 Introgen Therapeutics Inc Neues verfahren zur herstellung und reinigung von adenovirusvektoren
CN101208425B (zh) * 2004-12-13 2011-01-26 坎吉有限公司 产生复制缺陷型腺病毒的细胞系
US8574595B2 (en) * 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
EP1736538A1 (de) * 2005-06-21 2006-12-27 Cytos Biotechnology AG Prozess für die preparative Reinigung von Virus-ähnlichen Partikeln (VLPs)
EP1907537A4 (de) * 2005-07-14 2010-11-10 Mayo Foundation Paramyxoviridae-virus-zubereitungen
CA2633087C (en) * 2005-12-12 2014-12-02 Canji, Inc. Adenoviral expression vectors
JP2010504979A (ja) * 2006-09-29 2010-02-18 カンジ，インコーポレイテッド 遺伝子治療のための方法および組成物
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
EP3192874B1 (de) 2008-06-18 2019-10-16 Oxford BioMedica (UK) Limited Virusreinigung
HUE029265T2 (en) * 2008-10-27 2017-02-28 Glaxosmithkline Biologicals Sa Method of purifying carbohydrates from the group streptococci
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
EP2461826A2 (de) 2009-08-07 2012-06-13 Transgene SA Zusammensetzung zur behandlung von hbv-infektionen
KR101820980B1 (ko) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
DE102010046817A1 (de) 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
CA2819552C (en) 2010-12-09 2023-09-26 Institut Pasteur Mgmt-based method for obtaining high yield of recombinant protein expression
US9610354B2 (en) 2011-04-18 2017-04-04 National Center Of Neurology And Psychiatry Drug delivery particle and method for producing the same
TWI575070B (zh) 2011-07-12 2017-03-21 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
CN103842501B (zh) * 2011-10-05 2017-12-08 莫尔梅德股份有限公司 病毒载体纯化系统
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
PL2825640T3 (pl) 2012-03-12 2016-10-31 Partie rekombinowanych adenowirusów o zmienionych końcach
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
AP2014007994A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against rsv
CN103571800B (zh) * 2012-07-27 2018-04-24 江苏康润生物科技有限公司 一种去除疫苗中宿主dna的方法
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
PE20151867A1 (es) 2013-04-25 2016-01-07 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
US9663766B2 (en) * 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
MY193584A (en) 2016-04-05 2022-10-19 Janssen Vaccines & Prevention Bv Vaccine against rsv
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
KR102573534B1 (ko) 2016-05-12 2023-08-31 얀센 백신스 앤드 프리벤션 비.브이. 강력하고 균형 잡힌 양방향성 프로모터
US10953087B2 (en) 2016-05-30 2021-03-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
WO2017220499A1 (en) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
JP7016136B2 (ja) 2016-09-05 2022-02-04 国立研究開発法人科学技術振興機構 病原性微生物検出のための方法及びキット
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
JP7078620B2 (ja) 2016-11-16 2022-05-31 イミュノミック セラピューティックス， インコーポレイテッド アレルギーの治療のための核酸
CA3053212C (en) 2017-02-09 2021-04-13 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
JP7610349B2 (ja) 2017-04-22 2025-01-08 イミュノミック セラピューティックス， インコーポレイテッド 改良ｌａｍｐ構築物
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
CN111163800A (zh) 2017-09-15 2020-05-15 扬森疫苗与预防公司 用于安全诱导针对rsv的免疫的方法
US11603527B2 (en) * 2017-12-27 2023-03-14 Global Life Sciences Solutions Usa Llc Method and kit for viral vector isolation
JP7329851B2 (ja) * 2018-03-02 2023-08-21 国立研究開発法人科学技術振興機構 酵素反応生成物の検出方法
GB201806736D0 (en) * 2018-04-25 2018-06-06 Ge Healthcare Bioprocess R&D Ab Method for virus purification
US12398195B2 (en) 2018-05-15 2025-08-26 Immunomic Therapeutics, Inc. Lamp constructs comprising allergens
KR102782761B1 (ko) 2018-09-21 2025-03-14 유니버시티 오브 코네티컷 인간의 앤젤만 증후군에서 부계 ube3a 유전자 발현을 복원하기 위한 조성물 및 방법
JP7233880B2 (ja) * 2018-10-22 2023-03-07 キヤノンメディカルシステムズ株式会社 ウイルスｒｎａ単離方法及びウイルス定量方法
EP3880243A1 (de) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilisierte präfusionierte rsv-f-proteine
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020172509A1 (en) 2019-02-21 2020-08-27 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
WO2021077051A1 (en) 2019-10-18 2021-04-22 Immunomic Therapeutics, Inc Improved lamp constructs comprising cancer antigens
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
CN116261483B (zh) * 2020-08-18 2026-01-27 赛多利斯比亚分离有限责任公司 多模式金属亲和加工衣壳
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use
WO2025158316A1 (en) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Ovarian neoantigens and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004696A1 (en) * 1983-05-31 1984-12-06 Baxter Travenol Lab Particle adsorption
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5447859A (en) * 1993-07-16 1995-09-05 Viagene Method for the purification or removal of retroviruses using sulfated cellulose

Also Published As

Publication number Publication date
WO1996027677A3 (en) 1997-01-16
EP1686180A3 (de) 2006-08-09
DE69636217D1 (de) 2006-07-20
DK0813606T3 (da) 2006-10-02
EP0813606B1 (de) 2006-06-07
EP0813606A2 (de) 1997-12-29
PT813606E (pt) 2006-10-31
EP1686180A2 (de) 2006-08-02
AR001177A1 (es) 1997-09-24
DE69636217T2 (de) 2007-04-26
JP4182445B2 (ja) 2008-11-19
ES2264801T3 (es) 2007-01-16
US5837520A (en) 1998-11-17
JP2006271396A (ja) 2006-10-12
JP3858200B2 (ja) 2006-12-13
WO1996027677A2 (en) 1996-09-12
ZA961849B (en) 1997-08-27
AU5421396A (en) 1996-09-23
JP2000510682A (ja) 2000-08-22

Similar Documents

Publication Publication Date Title
ATE329045T1 (de) Verfahren zur aufreinigung von rekombinanten, viralen vektoren welche ein therapeutisches gen enthalten
DE69331507D1 (de) Verfahren zur Reinigung von menschlichem, rekombinantem Serumalbumin
DE69632887D1 (de) Verfahren zur zweckmässige Herstellung von Transglutaminase durch DNA-Rekombination
DE69627613D1 (de) Verfahren zur Rückgewinnung von Substraten
DE69407638D1 (de) Verfahren zur Fraktionierung von Blutmaterial
DE69806981D1 (de) Verfahren zur Kontrastverbesserung von Bildsequenzen
DE69019074D1 (de) Verfahren zur Fraktionierung von Plasmaproteinen.
DE69807962D1 (de) Verfahren zur Reinigung von rohem 1,1,1,3,3-Pentafluorpropan
DE3870724D1 (de) Verfahren zur rueckgewinnung von hochreinem m-ethylphenol.
DE69400257D1 (de) Verfahren zur Reinigung von Pentafluorethan
DE59804785D1 (de) Verbessertes Verfahren zur Stabilisierung von Proteinen
DE59603541D1 (de) Verfahren zur Reinigung von Bisphenol-A
DE69227621D1 (de) Verfahren zur Raffinierung von Zein
DE69320568D1 (de) Verfahren zur Rückgewinnung von Gruppe VIII Edelmetallen
DE69502313D1 (de) Verfahren zur biologischen Reinigung von Gasströmen
DE59002817D1 (de) Verfahren zur kontinuierlichen Reinigung von Caprolactam.
DE69633579D1 (de) Verfahren zur Rückgewinnung von Quecksilber
DE69304638D1 (de) Verfahren zur Reinigung von 1,1,1,2-Tetrafluorethan
DE69008825D1 (de) Verfahren zur Reinigung von Phagen-DNA.
DE69707848D1 (de) Verfahren zur Reinigung von Acetonitril
DE69319496D1 (de) Verfahren zur Rückgewinnung von verbrauchtem Rhenium
DE69505335D1 (de) Verfahren zur Reinigung von Methacrylsäure
DE59505969D1 (de) Verfahren zur Abtrennung von Chlorwasserstoff
DE69010155D1 (de) Verfahren zur Trennung von Aminosäuren.
DE69300901D1 (de) Verfahren zur Reinigung von 1,1,1,2-Tetrafluorethan.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0813606

Country of ref document: EP